Skip to content
Trial Eligibility
Menu

Lung Cancer Clinical Trials near Boston, MA

167 studies for Lung Cancer are recruiting at 279 sites within 50 miles of Boston, Massachusetts, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Lung Cancer trials in the US or all trials near Boston.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Lung Cancer studies enrolling near Boston

Showing the 50 nearest of 167 studies.
  1. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    NCT04267848

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Boston Medical Center (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    14 sites within 50 mi
  2. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    NCT06096844

    • Phase 3
    • Ages 70 years and older
    • Sex: All

    Nearest sites: Tufts Medical Center (Boston, MA); Dana-Farber Cancer Institute at Boston Medical Center - Brighton (Brighton, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  3. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    NCT06767514

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Clinical Study Site (Boston, MA); Clinical Study Site (Brighton, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  4. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    NCT04389632

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Beth Israel Deaconess Medical Center,East Campus Research Pharmacy (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  5. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    NCT04613596

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Dana-Farber Cancer Institute at St. Elizabeths Medical Center (Brighton, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  6. Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

    NCT04777994

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center /ID# 252009 (Boston, MA); Dana-Farber Cancer Institute /ID# 249642 (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  7. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    NCT05098132

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana-Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  8. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    NCT05579366

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  9. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    NCT06119581

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Boston Medical Center (Boston, MA); Lahey Hospital & Medical Center (Burlington, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  10. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    NCT06667076

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Boston University Medical Center (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  11. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    NCT06706076

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana-Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  12. Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

    NCT06769126

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Tufts Medical Center (Boston, MA); Lahey Hospital and Medical Center (Burlington, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  13. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    NCT07090499

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Brigham and Women's Hospital (Boston, MA); Dana-Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  14. DNA Analysis of Blood and Tissue From Patients With Lung Cancer

    NCT00471978

    • Observational
    • Ages 18 to 120 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: Harvard School of Public Health (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  15. Stereotactic Magnetic Resonance Guided Radiation Therapy

    NCT04115254

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Brigham & Women's Hospital (Boston, MA); Dana Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  16. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    NCT04370587

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  17. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    NCT04585750

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  18. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

    NCT04665206

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  19. Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

    NCT04789486

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Brigham and Women's Hospital (Boston, MA); Dana Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  20. Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

    NCT04899908

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Brigham and Women's Hospital (Boston, MA); Dana Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  21. Biology of Young Lung Cancer Study: The YOUNG LUNG Study

    NCT05265429

    • Observational
    • Ages 15 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  22. A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

    NCT05652686

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  23. Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

    NCT05797168

    • Phase 1/2
    • Ages 18 to 130 years
    • Sex: All

    Nearest sites: Research Site (Boston, MA); Research Site (Providence, RI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  24. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    NCT05877599

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Boston, MA); Research Site (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  25. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    NCT05983432

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  26. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    NCT06040541

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  27. A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

    NCT06095505

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  28. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    NCT06150664

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana-Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  29. Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

    NCT06196008

    • Interventional
    • Ages 18 years and older
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: Massachusetts General Hospital (MGH) / Harvard (Boston, MA); Lahey Hospital & Medical Center (Burlington, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  30. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    NCT06253871

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  31. Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

    NCT06357533

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Boston, MA); Research Site (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  32. A Registry for People With Lung Cancer

    NCT06424327

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Brigham and Women's Hospital (Data Collection Only) (Boston, MA); Massachusetts General Hospital Cancer Center (Data Collection Only) (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  33. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    NCT06561685

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  34. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    NCT06623422

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Hospital ( Site 0155) (Boston, MA); Massachusetts General Hospital ( Site 0136) (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  35. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    NCT06625775

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Insitute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  36. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

    NCT06657222

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  37. A Study of MGC028 in Participants With Advanced Solid Tumors

    NCT06723236

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber/Harvard Cancer Center (Boston, MA); Mass General Brigham (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  38. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    NCT06784193

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  39. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    NCT06793215

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Massachusetts General Hospital (Boston, MA); University of Massachusetts Memorial Medical Center (Worcester, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  40. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    NCT06835569

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Boston, MA); Research Site (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  41. A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

    NCT06914128

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute - Oncology Department (Boston, MA); Massachusetts General Hospital - Neurology (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  42. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

    NCT06922591

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  43. Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

    NCT07149363

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (MGH) (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  44. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    NCT07182149

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Normunity Investigational Site (Boston, MA); Normunity Investigational Site (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  45. Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

    NCT07405190

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  46. A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

    NCT07491497

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Center (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  47. Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

    NCT02984761

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest site: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. Boston Lung Cancer Study (Molecular and Genetic Analysis of Lung Cancer)

    NCT03029325

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

    NCT03093116

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest site: Massachusetts General Hospital, (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

    NCT03191149

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Massachusetts General Hospital Cancer Center (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Lung Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.